Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder
Journal of Psychiatric Practice – May 01, 2025
Source: OpenAlex
Summary
Psilocybin, a potent hallucinogen, shows highly variable effects for major depressive disorder. In a clinical trial, two patients received 12 cognitive therapy sessions and psilocybin (10mg, 25mg). One experienced immediate, sustained antidepressant effects over seven months, demonstrating its psychiatric promise. Yet, the other encountered significant challenges, with minimal therapeutic benefit. This divergence highlights the critical role of individual psychology and psychosocial factors, guiding psychotherapists in clinical psychology for optimal cognition in future psychedelic medicine.
Abstract
We present divergent experiences of 2 patients who participated in a clinical trial of psilocybin-assisted cognitive behavioral therapy for major depressive disorder. Both patients participated in an open trial involving 2 drug administration sessions separated by one month (10 and 25 mg, respectively) along with 12 sessions of cognitive behavioral therapy. The first of the 2 patients had powerful and beneficial experiences on psilocybin that led to immediate and sustained antidepressant effects over the 7-month study. The second participant reported significant challenges with psilocybin and minimal to no antidepressant effects following the drug administration. We present the clinicians’ experiences who treated both patients. Finally, we theorize and discuss areas of future research to elucidate how psilocybin can yield the greatest psychiatric benefit, the conditions within the patient that can lead to (or inhibit) psychiatric benefit, and the psychosocial environment that can best facilitate psilocybin therapy.